Administration of M-cholinoblockers after prostatic surgery


如何引用文章

全文:

详细

Some patients after prostatic surgery demonstrate hyperactivity symptoms. These symptoms can be relieved by M-cholinoblockers. We analysed prospectively the results of treatment of 23 patients (mean age 69.8 years) with clinically localized prostatic cancer after radical retropubic prostatectomy. The patients were examined before and after 3 months of treatment. All the patients received tolterodin (urotol) per os in a dose 2 mg twice a day. The results of the therapy showed that M-cholinoblocker tolterodin (urotol) is effective and well tolerated in patients with hyperactive symptoms after radical prostatectomy.

参考

  1. Stewart W. F., Van Rooyen J. B., Cundiff G. W. et al. Prevalence and burden of overactive bladder in the United States. Wld J. Urol. 2003; 20: 327.
  2. Glasser D. B., Carson C. et al. Prevalence of storage and voiding symptoms among men aged 40 years and older in a US population-based study. Int. J. C1in. Pract. 2007; 61: 1294-1300.
  3. Abrams P., Kaplan S. et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urol. (Baltimore) 2006; : 999-1004.
  4. Helfand B. T., Evans R. M., McVary K. T. Prevalence of medical therapies in men and women with overactive bladder symptoms. In: poster presentation at 2009 American Urological Association Meeting, April 25-30, 2009. Chicago, IL., 2009. Poster 1942.
  5. Lee J. Y., Kim H. W. et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. Br. J. Urol. Int. 2004; 95: 1117-1119.
  6. Mitterberger M., Pallwein L. et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. Br. J. Urol. Int. 2007; 99: 831-835.
  7. Huckabay C., Twiss C., Berger A. et al. A urodynamics protocol to optimally assess men with post-prostatectomy incontinence. Neurourol. and Urodynam. 2005; 24: 622-626.
  8. Brading A., Pessina F., Esposito L., Symes S. Effects of metabolic stress and ischaemia on the bladder, and the relationship with bladder overactivity. Scand. J. Urol. Nephrol. Suppl. 2004; 215: 84-92.
  9. Groutz A., Blaivas J. C., Chaikin D. C. et al. The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study. J. Urol. (Baltimore) 2000; 163: 1767- 1770.
  10. Giannantoni A., Mearini E., Di Stassi S. M. et al. Assesment of bladder and urethral sphincter function before and after radical retropubic prostatectomy. J. Urol. (Baltimore) 2004; 171: 1556-1563.
  11. Kielb S. J., Clemens J. Q. Comprehensive urodynamics evaluation of 146 men with incontinence after radical prostatectomy. Urology 2005; 66: 392-396.
  12. Majoros A., Bach D., Keszthelyi A. et al. Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study). Neurourol. amd Urodynam. 2006; (1): 2-7.
  13. Andersson K. E. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003; 62 (Suppl. 2): 3-10.
  14. Mitterberger M., Pallwein L., Gradl J. et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. Br. J. Urol. Int. 2007; 99: 831-835.
  15. Machino R., Kakizaki H., Ameda K. et al. Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol. and Urodynam. 2002; 21: 444-449.
  16. Herbison P., Hay-Smith J., Ellis G., More K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br. Med. J. 2003; 326: 841-844.
  17. Chapple C., Khullar V., Gabriel Z., Dooley J. A. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol. 2005; 48: 5-26.
  18. Mitropoulos D., Papadoukakis S., Zervas A. et al. Efficacy of tolterodine in preventing urge incontinence immediately after prostatectomy. Int. Urol. Nephrol. 2006; 38(2): 263-268.
  19. Sussman D. O., Kraus S. R., Carlsson M., Guan Z. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr. Med. Res. Opin. 2007; 23: 777-781.
  20. Haab F., Stewart L., Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once daily treatment for overactive bladder. Eur. Urol. 2004; 45(4): 420- 429.
  21. Agarwal A., Raza M., Sinfhal V. et al. The efficacy of tolterodine for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Anesth. Analg. 2005; 101: 1065-1067.
  22. Tauzin-Fin P., Sesay M., Svartz L. et al. Sublingual oxybutynin reduces postoperative pain related to indwelling bladder catheter after radical retropubic prostatectomy. Br. J. Anaesth. 2007; 99(4): 572-575.
  23. Kay G. G., Granvlle L. J. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin. Ther. 2005; 27: 127-138.
  24. Scheife R., Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder. Clin. Ther. 2005; 27(2): 114-153.
  25. Sand P. K., Miklos J., Ritter H., Apell R. A comparison of extended - release oxybutynin and tolterodine for treatment of overactive bladder in women. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2004; 15: 243-248.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##